Review

Is the C-C Motif Ligand 2–C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?

Hiroaki Iwamoto, Kouji Izumi * and Atsushi Mizokami

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8641, Ishikawa, Japan; hiroaki017@yahoo.co.jp (H.I.); mizokami@staff.kanazawa-u.ac.jp (A.M.)

* Correspondence: azuizu2003@yahoo.co.jp; Tel.: +81-76-265-2393; Fax: +81-76-234-4263

Received: 21 November 2020; Accepted: 5 December 2020; Published: 7 December 2020

Abstract: C-C motif ligand 2 (CCL2) was originally reported as a chemical mediator attracting mononuclear cells to inflammatory tissue. Many studies have reported that CCL2 can directly activate cancer cells through a variety of mechanisms. CCL2 can also promote cancer progression indirectly through increasing the recruitment of tumor-associated macrophages into the tumor microenvironment. The role of CCL2 in cancer progression has gradually been understood, and various preclinical cancer models elucidate that CCL2 and its receptor C-C chemokine receptor 2 (CCR2) are attractive targets for intervention in cancer development. However, clinically available drugs that regulate the CCL2–CCR2 axis as anticancer agents are not available at this time. The complete elucidation of not only the oncological but also the physiological functions of the CCL2–CCR2 axis is required for achieving a satisfactory effect of the CCL2–CCR2 axis-targeted therapy.

Keywords: biomarker; CCL2; CCR2; chemokine; immunotherapy; cancer; tumor; progression; metastasis

1. Introduction

C-C motif ligand 2 (CCL2) was discovered first among CC chemokines in 1989 and helped to propel subsequent discoveries of other CC chemokines [1]. CCL2, also known as monocyte chemoattractant protein-1 (MCP-1), is composed of 76 amino acids and has a size of 13 kDa [2]. CCL2 is expressed in a wide range of cells, including endothelial cells, epithelial cells, myeloid cells, smooth muscle cells, and fibroblasts [3]. The biological function of CCL2 is mediated through its G protein-coupled receptor C-C chemokine receptor 2 (CCR2) [4]. Although CCR2 also binds to CCL7, CCL8, CCL12, and CCL13, CCL2 most potently activates a CCR2-mediated signaling pathway [5]. CCL2 has two specific high-affinity receptors, CCR2A and CCR2B, and activation of monocytes by CCL2 mediates monocyte infiltration into tissues in inflammatory diseases [6]. The number of studies on the role of CCL2 in the development of obesity, diabetes, cardiovascular diseases, insulinis, diabetic nephropathy, and diabetic retinopathy has increased exponentially over time [7–9]. In addition, studies on the role of CCL2 in cancer have been reported since 2000, and the role of CCL2 in the tumor microenvironment, immuno-oncology, and cancer cells has been the main topic of CCL2 research nowadays. Other chemokines, such as CCL18 and CCL20, have been reported to play important roles in the growth and migration of various cancers and have been shown to be promising as tumor markers and therapeutic targets, but have not yet reached clinical application [10,11]. Although the roles of CCL2 in cancer progression have been understood gradually, drugs modulating the CCL2–CCR2 axis as anticancer agents are clinically not available except for administration in clinical trials. Because of the multifunctional nature of CCL2, the blockade of the CCL2–CCR2 axis may cause unexpected effects on cancer patients. The potentials
and limitations of CCL2–CCR2 axis targeted as cancer immunotherapy and a diagnostic tool are described in this review.

2. Role of the CCL2–CCR2 Axis in Cancer Cells

2.1. The Direct Effects of CCL2 on Cancer Cells

There is a number of studies suggesting that CCL2 can activate cancer cells through a variety of mechanisms. Initially, CCL2 was focused on and studied as a key molecule in the migration and proliferation of prostate cancer cells [12]. CCL2 directly stimulates prostate cancer cell proliferation and migration via activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and Rac GTPase, respectively [13]. CCL2 induces cancer cell migration and contributes to the early stages of metastasis by interacting with CCR2 expressed on cancer cells [14]. Cancer cells acquire a migratory and invasive phenotype that invades adjacent tissues by disrupting the extracellular matrix and migrates toward the blood and lymphatic vessels in an early stage of CCL2-induced metastasis [15,16]. CCL2-dependent Signal Transducers and Activator of Transcription 3 (STAT3) activation and the induction of epithelial-mesenchymal transition (EMT) pathways have been reported, and CCL2 modulates the expression of EMT-related proteins, matrix metalloproteinase (MMP) 2, MMP9, Vimentin, Snail, and E-cadherin in cancer cells [17–27]. Interruption of the CCL2–CCR2 axis can suppress EMT and prostate cancer cell migration and invasion, providing a critical mechanism linking CCL2 and cancer metastasis [19,22–24,27,28]. CCL2 may be a starting point for subsequent chemokine cascades inducing prostate cancer cell activation [29]. CCL2 contributes to the acquisition of resistance to taxane chemotherapies such as docetaxel and cabazitaxel in prostate cancer cells [30,31]. CCL2 may also contribute to the acquisition of tamoxifen resistance in breast cancer cells [32].

Although a great number of the studies focusing on the function of CCL2 in cancer progression used prostate and breast cancer cells, more recent CCL2 studies have incorporated colorectal, lung, gynecological, gastric, and other types of cancer cells. Akt activation by phosphatidylinositol phosphate kinase gamma (PIPKIγ)-mediated STAT3 phosphorylation induces CCL2 expression in colorectal cancer cells and silencing PIPKIγ greatly decreases CCL2 expression at both the mRNA and protein levels, leading to reduced chemotaxis of cancer cells to macrophages [33]. In metastatic colorectal cancer liver metastatic model mice, administration of CCR2 inhibitor improves the chemotherapy response and prolongs overall survival of cancer-bearing mice [34]. Targeting CCR2 with its antagonist also suppresses viability, motility, and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells [35]. The CCL2–CCR2 axis enhances interleukin (IL)-6-induced EMT by cooperatively activating STAT3–Twist signaling in non-small cell lung cancer cells [20]. Although the detailed mechanism is not clarified, CCL2 promotes invasion and adhesion of human ovarian cancer cells, and CCL2 blockade can enhance the cytotoxic effect of paclitaxel and carboplatin therapies in ovarian cancer [36,37]. CCL2 also contributes to the acquisition of resistance to docetaxel in lung cancer and resistance to cisplatin in gastric cancer [38,39].

2.2. The Effects of CCL2 on Cancer Cell via Tumor Microenvironment

Since CCL2 is also known by the alias monocyte chemoattractant protein-1 and activates macrophages, inactivation of cancer cells by the inhibition of the CCL2–CCR2 axis are partly presumed to be caused by the reduction of tumor-associated macrophages (TAMs) at the primary and metastatic site, inducing the destruction of the immunosuppressive tumor microenvironment and the susceptibility to the antitumor T lymphocyte response. TAMs play a major role in cancer progression by affecting diverse processes such as immunosuppression, angiogenesis, and tumor cell proliferation and metastasis during cancer progression [40–42]. It was reported that CCL2-positive prostate cancer tissues have more macrophage infiltration than CCL2-negative cancer tissues, CCL2 can also promote prostate cancer progression indirectly by increasing the recruitment of TAMs into the tumor microenvironment [28,43]. An increase in the number of TAMs generally shortens survival
and increases the grade and stage of cancer. Specifically, they have been reported in gastric cancer, breast cancer, prostate cancer, classical Hodgkin’s lymphoma, kidney cancer, nasopharyngeal cancer, and glioma [44–52]. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of TAMs [53]. Radiotherapy leads to a significant increase in CCL2 production by pancreatic ductal adenocarcinoma cells and recruitment of TAMs, and neutralizing anti-CCL2 antibody selectively inhibits radiotherapy-dependent recruitment of TAMs and delays tumor growth in combination with radiotherapy [54].

Myeloid-derived suppressor cells (MDSCs) also foster cancer cell activity by suppression of T lymphocytes and natural killer cells, while simultaneously they can recruit regulatory T lymphocytes to further promote immunosuppression [55]. Deletion of CCL2 blocked progression from dysplasia to adenocarcinoma and reduced the number of colonic MDSCs in a spontaneous mouse model of colitis-associated colorectal cancer. CCL2 induces MDSC accumulation in evolving colonic tumors and enhances polymorphonuclear-MDSC immunosuppressive features, resulting in T lymphocyte suppression by polymorphonuclear-MDSCs in a STAT3-mediated manner [56]. In a mouse liver cancer model, fibroblast activation protein (FAP)–STAT3–CCL2 signaling in cancer-associated fibroblasts (CAFs) promoted tumor growth by enhancing MDSC mobilization and FAP-mediated tumor promotion, and MDSC mobilization in CAF was abolished in CCR2-deficient mice [57].

CAFs are stromal components and play an important role in tumor progression by regulating the tumor microenvironment and primarily releasing proteolytic enzymes, growth factors, and cytokines [58,59]. Pancreatic ductal adenocarcinoma cells educate fibroblasts through the secretion of CCL2 and IL-8, leading to CAFs and similar metastasis-related fibroblasts. CAFs and metastasis-related fibroblasts promoted angiogenesis and tumor progression by interacting with cancer cells [60]. Moreover, CCL2 involves tumor cell extravasation through the endothelium. Cancer cell-derived CCL2 activates vascular endothelial cells to increase vascular permeability and increases cancer cell extravasation and metastasis in vivo colon cancer model. CCL2-induced vascular permeability and metastasis are dependent on Janus kinase2 (JAK2)–STAT5 and p38 Mitogen-activated Protein Kinase (MAPK) signaling [61]. In lung cancer cells, endothelial CCR2 expression is reported to be an important factor for cancer cell extravasation and pulmonary metastasis as well [23].

3. The CCL2–CCR2 Axis as a Biomarker

Consistent with the role of CCL2 in cancer progression, serum CCL2 levels and CCL2 expression levels in tumor tissue have been reported as potential biomarkers in a variety of cancer patients (Table 1).

| Cancer Types     | Target                                      | Size | Specimens  | Biomarker                          | Variables                                           | References |
|------------------|---------------------------------------------|------|------------|------------------------------------|-----------------------------------------------------|------------|
| Prostate cancer  | Men with and without prostate cancer        | 379  | Blood tissue | High serum CCL2 levels             | Breast cancer                                       | [62]       |
|                  | Prostate cancer patients                     | 255  |            | Serum CCL2 level ≥ 320 pg/mL       | Poor OS, Poor PCSS, Advanced cancer stage, Poor histological grade |           |
| Prostate cancer  | Men with and without prostate cancer        | 55   | Prostate tissue | CCL2 positive in tissue            | Breast cancer                                       | [28]       |
|                  | Prostate cancer patients                     | 35   | Primary tumor tissue |            | Poor OS                             |            |
| Colorectal cancer| Preoperative colorectal cancer patients     | 45   | Blood tissue | Preoperative serum CCL2 levels     | Poor 5-year survival rate                          | [63]       |
| Colorectal cancer| Colorectal cancer patients with liver metastases | 87   | Hepatectomy tissue | High expression of CCL2 levels     | Poor survival after hepatectomy for colorectal liver metastases | [64]       |
| Colorectal cancer| Colorectal cancer patients                   | 245  | Primary tumor tissue | High expression of CCL2 levels     | Liver metastasis                                   | [65]       |
| Cancer Types   | Target                                                                 | Size | Specimens        | Biomarker                                  | Variables                                  | References |
|---------------|------------------------------------------------------------------------|------|------------------|--------------------------------------------|--------------------------------------------|------------|
| HCC           | Resectable HCC patients, Chronic hepatitis B patients, Asymptomatic hepatitis B and C virus carriers | 299  | Blood tissue     | High serum CCL2 levels                      | HCC                                        | [66]       |
|               |                                                                         |      |                  | High serum alpha-fetoprotein and CCL2 levels | Disease stage of HCC                       |            |
| HCC           | HCC patients                                                           | 57   | Primary tumor tissue | High expression of CCL2 gene               | Poor survival of HCC in early-stage disease | [67]       |
| Breast cancer | Breast cancer patients                                                 | 135  | Blood tissue     | High serum CCL2 levels                      | Advanced cancer stage, Lymph node metastasis | [68]       |
| Breast cancer | Breast cancer patients                                                 | 137  | Primary tumor tissue | High frequency of CCL2 positive cancer cells and CD14+ TAMs | Cancer recurrence                         | [69]       |
| Breast cancer | Breast cancer patients                                                 | 427  | Primary tumor tissue | Stromal CCL2                                | Poor RFS with basal-like breast cancer      | [70]       |
| Breast cancer | Breast invasive ductal carcinoma patients                               | 27   | Primary tumor tissue | High expression of CCL2                    | Cancer recurrence                          | [71]       |
| Pancreatic cancer | Suspected pancreatic neoplasm patients                               | 212  | Blood tissue     | High serum CCL2 levels                      | Pancreatic cancer                          | [72]       |
| Pancreatic cancer | Pancreatic cancer patients                                           | 68   | Blood tissue     | High serum CCL2 levels                      | Poor survival and prognosis                 | [73]       |
| Pancreatic cancer | Pancreatic cancer patients, Patients with benign pancreatic tumors   | 108  | Blood tissue     | High serum CCL2 levels                      | Poor survival after pancreatic resection    | [74]       |
| Pancreatic cancer | Pancreatic cancer patients                                             | 70   | Primary tumor tissue | High expression of CCL2 and IL-8 cytokine levels | Cachexia                                   | [75]       |
| Malignant lymphoma | Diffuse large B-cell lymphoma patients                               | 221  | Primary tumor tissue | High expression of CCL2 and CCR2           | Poor OS, Poor PFS, Poor clinicopathological characteristics | [76]       |
| Malignant lymphoma | Non-Hodgkin’s lymphoma patients, Hodgkin’s lymphoma patients, Healthy subjects | 81   | Blood tissue     | High serum CCL2 levels                      | Severity, Low benefit from treatment        | [77]       |
| Malignant lymphoma | Non-Hodgkin’s lymphoma patients, Reactive tonsils                    | 28   | Primary tumor tissue | High expression of CCL2                    | Poor histological grade                    | [78]       |
| Gastric cancer | Gastric cancer patients, Healthy subjects                             | 80   | Blood tissue     | High serum CCL2 levels                      | Gastric cancer                             | [79]       |
| Gastric cancer | Gastric cancer patients, Healthy subjects                             | 108  | Blood tissue     | Preoperative serum CCL2 levels              | Lymph node metastasis                      | [80]       |
| Gastric cancer | Gastric cancer patients, Healthy subjects                             | 77   | Blood tissue     | High serum CCL2 levels                      | Poor responsive to chemotherapy             | [81]       |
| Gastric cancer | Gastric cancer patients, Healthy subjects                             | 68   | Primary tumor tissue | High expression of CCL2                    | Advanced gastric cancer stage               | [82]       |
| Gastric cancer | Gastric cancer patients, Healthy subjects                             | 178  | Primary tumor tissue | High expression of CCL2 and Snail           | Poor prognosis                             | [83]       |
| Ovarian cancer | Ovarian cancer patients, Benign ovarian cyst patients, Healthy women  | 195  | Blood tissue     | High serum CCL2 levels                      | Ovarian cancer, Poor histological malignancy | [84]       |
Table 1. Cont.

| Cancer Types                     | Target                                      | Size | Specimens          | Biomarker                      | Variables                                | References |
|----------------------------------|---------------------------------------------|------|--------------------|--------------------------------|------------------------------------------|------------|
| Ovarian cancer                   | Ovarian cancer patients                     | 37   | Primary tumor tissue| High expression of CCL2 mRNA   | Objective complete response, Poor chemosensitivity, Poor PFS | [88]       |
| Lung cancer                      | Lung cancer patients, Non-lung cancer subjects | 283  | Blood tissue       | High serum CCL2 levels         | Lung cancer                             | [89]       |
| Lung cancer                      | Lung cancer patients                        | 719  | Primary tumor tissue| High expression of CCL2        | Poor OS, Poor PFS                        | [90]       |
| Malignant pleural mesothelioma   | Malignant pleural mesothelioma patients, Healthy subjects | 447  | Blood tissue       | High serum CCL2 levels         | Advanced malignant pleural mesothelioma | [91]       |
| Bladder cancer                   | Bladder cancer patients                     | 80   | Urine              | High CCL2 levels in the urine  | Advanced cancer stage, Poor histological grade | [92]       |
| Kidney cancer                    | Kidney cancer patients                      | 114  | Primary tumor tissue| High expression of CCL2        | Advanced clinical stage, Poor OS         | [93]       |
| Kidney cancer                    | Non-metastatic kidney cancer patients       | 268  | Primary tumor tissue| High expression of CCL2 and CCR2 | OS after surgical treatment, RFS after surgical treatment | [94]       |
| Laryngeal cancer                 | Laryngeal cancer patients                   | 297  | Blood tissue       | High serum CCL2 and TNF-α levels | Poor OS, Poor distant metastasis-free survival | [95]       |
| Thyroid cancer                   | Papillary thyroid cancer patients           | 115  | Primary tumor tissue| High expression of CCL2        | Cancer recurrence                        | [96]       |
| Malignant glioma                 | Malignant glioma patients, Benign glioma patients, Patients with nontumor disorders of the central nervous system | 35   | Cerebrospinal fluid| High CCL2 levels               | Malignant glioma                         | [97]       |

CCL2, C-C Motif Ligand 2; CCR2, C-C Chemokine receptor 2; OS, overall survival; PCSS, prostate cancer-specific survival; HCC, hepatocellular carcinoma; TAM, tumor-associated macrophage; RFS, recurrence-free survival; VEGF, vascular endothelial growth factor.

3.1. Prostate Cancer

The usefulness of serum CCL2 in prostate cancer patients was supported by a study using the serum samples of 255 and 124 men with and without prostate cancer, respectively, which reported that serum CCL2 levels in men with prostate cancer were significantly higher than those without. In addition, among the 255 patients with prostate cancer, those with serum CCL2 level \( \geq 320 \text{ pg/mL} \) had significantly poorer overall survival and prostate cancer-specific survival, higher TNM stages, and worse histological grade than those with serum CCL2 level \( < 320 \text{ pg/mL} \), indicating the potential of serum CCL2 level as a prognostic biomarker as well [62]. The outcome of prostate cancer patients with CCL2-positive tissues was significantly worse with lower survival time than those patients with CCL2-negative tissues [28].

3.2. Colorectal Cancer

When the preoperative serum CCL2 concentration of 45 colorectal cancer patients was measured, the 5-year survival rate was significantly better in the group with low preoperative CCL2 level than in the group with high preoperative CCL2 level [63]. In a study examining CCL2 expression in 87 hepatectomy specimens of colorectal cancer liver metastases, CCL2 levels were associated with cancer progression and were prognostic markers of survival after hepatectomy for colorectal liver metastases [64]. As a result of examining the expression level of CCL2 from 245 colorectal cancer samples, the high expression level of CCL2 in the primary lesion was a significant marker for predicting liver metastasis [65].
3.3. Hepatocellular Carcinoma (HCC)

Serum CCL2 was significantly higher in HCC patients in a study that measured CCL2 levels from serum samples from 98 resectable HCCs, 101 patients with chronic hepatitis B, and 100 asymptomatic hepatitis B and C virus carriers. In addition, the serum CCL2 also correlated with the disease stage of HCC and the combination of alpha-fetoprotein and CCL2 has significantly superior discriminative ability than alpha-fetoprotein alone [66]. In examining resected specimens of 57 HCC patients, the CCL2 gene was one of the predictive markers for the survival of HCC, especially in early-stage disease [67].

3.4. Breast Cancer

Serum CCL2 levels in 135 breast cancer patients were measured and elevated and serum CCL2 levels were significantly correlated with advanced cancer stage and lymph node metastasis [68]. Immunohistochemistry to examine the frequency of TAMs and CCL2-expressing cells from paraffin blocks of 137 breast cancer patients found that high frequency of CCL2 positive cancer cells and CD14+ TAMs were significant risk factors for cancer recurrence [69]. Analysis of 427 breast cancer specimens suggests that stromal CCL2 is associated with reduced recurrence-free survival in patients with basal-like breast cancer and may be a predictor of prognosis [70]. Analysis of 151 breast cancer samples showed that high expression of CCL2 and vascular endothelial growth factor were a significant indicator of early recurrence of breast cancer [71]. Immunohistochemical analysis of CCL2 expression from 27 breast invasive ductal carcinoma specimens showed that CCL2 expression in tumor parenchyma significantly correlated with the histological grade of ductal infiltrative breast cancer [72].

3.5. Pancreatic Cancer

A study of 212 pancreatic cancer patients found that CCL2 serum levels in pancreatic cancer patients were significantly higher than in normal healthy subjects [73]. In a study examining serum CCL2 levels in 68 patients with pancreatic cancer, a high level of serum CCL2 was strongly associated with poor survival and prognosis [74]. An analysis of 483 pancreatic cancer patients showed that patients with pancreatic cancer with high CCL2 expression and low CD8+ T lymphocyte infiltration had significantly reduced survival [75]. CCL2 and IL-8 cytokine levels were found to be associated with poorer survival after pancreatic resection in a study analyzing the sera of 85 pancreatic cancer patients and 23 patients with benign pancreatic tumors [76]. CCL2 was found to be a ubiquitously expressed gene, including expression in adipose tissue, skeletal muscle, and pancreatic cancer cells, and was associated with cachexia in pancreatic cancer patients [77].

3.6. Malignant Lymphoma

CCL2 and CCR2 expression was analyzed by immunohistochemical staining and its correlations with clinicopathologic features and prognosis were evaluated in 221 patients with diffuse large B-cell lymphoma, and high expression of CCL2 or CCR2 was correlated with clinicopathological characteristics and indicated significantly poorer overall survival and progression-free survival [78]. In a study in 81 lymphoma patients, including 44 non-Hodgkin’s lymphoma (NHL), 37 Hodgkin’s lymphoma patients, and 20 healthy subjects as a control group, high serum levels of inflammatory markers, including CCL2, correlate with severity and low benefit from treatment [79]. In a study using samples of 20 NHL patients and 8 reactive tonsils, the level of CCL2 cDNA in patients with aggressive NHL was higher than in indolent tumors [80].

3.7. Gastric Cancer

As a result of examining the peripheral blood of 60 patients with gastric cancer and 20 healthy subjects, preoperative serum levels of CCL2 in patients with gastric cancer were significantly higher than those in healthy controls. In addition, preoperative serum CCL2 was significantly correlated with lymph node metastasis [81]. A study of serum CCL2 in 78 patients with gastric cancer and 30 healthy
controls showed that patients with gastric cancer with elevated serum CCL-2 levels were significantly less responsive to chemotherapy [82]. Measuring chemokine levels from the plasma of 66 gastric cancer patients and 11 healthy controls revealed CCL2 levels correlated with advanced gastric cancer stage [83]. In immunohistochemistry of 68 patients with gastric cancer, high CCL2 expression in tumor tissue showed significantly poor prognosis [84]. Similarly, as a result of immunohistochemical examination from clinical specimens of 178 gastric cancer patients, CCL2 and Snail were independent prognostic factors of gastric cancer [85]. Immunohistochemical staining of CCL2 expression in tumor tissue in 414 gastric cancer patients who underwent gastrectomy showed that the increased expression level of CCL2 was an independent prognostic factor for overall survival in patients with gastric cancer [86].

3.8. Ovarian Cancer

In a retrospective study including 86 ovarian cancer patients, 67 benign ovarian cysts, and 42 healthy women, ovarian cancer patients had significantly higher serum CCL2 levels, and serum CCL2 levels were statistically significantly correlated with histological malignancy [87]. In a study investigating CCL2 gene expression using tumor specimens from 37 ovarian cancer patients, CCL2 mRNA expression was correlated with objective complete response, chemosensitivity, and progression-free survival [88].

3.9. Lung Cancer and Malignant Pleural Mesothelioma

Comparing 142 lung cancer patients with 141 non-lung cancer subjects, CCL2 was significantly elevated in lung cancer patients [89]. Western blotting results from tissue specimens in 719 patients with lung cancer revealed that patients with high CCL2 expression had significantly worse overall survival and progression-free survival [90]. In a study of 50 patients with malignant pleural mesothelioma who may have been exposed to asbestos, 356 subjects who may have been exposed to asbestos but had no disease, and 41 healthy volunteers with no history of asbestos exposure, serum CCL2 levels were significantly elevated in patients with advanced malignant pleural mesothelioma [91].

3.10. Bladder and Kidney Cancers

Examining CCL2 levels in urine samples from 60 bladder cancer patients and 20 control healthy subjects revealed CCL2 levels in the urine of patients with bladder cancer correlated significantly with TNM stage and cancer grade [92]. Immunohistochemical analysis of 114 kidney surgical specimens showed that upregulation of CCL2 expression correlated with macrophage infiltration, clinical stage, and overall survival [93]. CCL2 and CCR2 were identified as independent risk factors for overall survival and recurrence-free survival after surgical treatment from a sample of 268 patients with non-metastatic kidney cancer [94].

3.11. Head and Neck Cancers

Examination of serum CCL2 and TNF-α in 297 patients with pretreatment laryngeal cancer showed that CCL2 and TNF-α levels were independent predictors of overall survival and distant metastasis-free survival [95]. Immunohistochemical staining of tissue specimens of 115 patients with papillary thyroid cancer showed that CCL2 expression levels were an independent predictor of recurrence [96]. CCL2 levels in cerebrospinal fluid samples from patients with malignant glioma were significantly higher than those from patients with benign glioma or healthy subjects [97].

4. The Development of the CCL2–CCR2 Axis-Targeted Agents

The effects of the orally administered CCR2 inhibitor PF-04136309 in combination with leucovorin (folinic acid), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with treatment-naïve locally advanced pancreatic ductal adenocarcinoma were assessed in a phase Ib study; ultimately, 16 (49%) of 33 patients receiving FOLFIRINOX plus PF-04136309 achieved an objective tumor response, with local tumor control achieved in 32 (97%) patients [98]. However, in another phase Ib study,
assessing PF-04136309 in combination with nab-paclitaxel and gemcitabine in 21 patients with previously untreated metastatic pancreatic ductal adenocarcinoma, the objective response rate with this treatment was only 23.8% [99]. The clinical utility of carlumab, a human antibody with high affinity and specificity for CCL2, was investigated in a phase I study of 44 patients with solid malignancies. In this study, patients with ovarian and prostate cancer achieved more than 50% CA125 and prostate-specific antigen (PSA) reduction and retained stable disease for 10.5 and 5 months, respectively [100]. The clinical benefit of carlumab was also investigated in 46 patients with metastatic castration-resistant prostate cancer previously treated with docetaxel in a phase II, open-label study. However, carlumab alone did not block the CCL2–CCR2 axis or show antitumor activity [101]. MLN1202, a humanized, neutralizing anti-CCR2 antibody was investigated in a phase II clinical trial for the treatment of 44 patients with bone metastasis, regardless of the primary site. Forty-one out of 43 eligible patients completed this study, with 7% having serious adverse events. The concentration in urine of N-telopeptide, a biomarker to measure bone turnover rates, decreased in 14% of the patients, suggesting a positive effect of the antibody in these patients [102]. A multicenter clinical trial was conducted in patients with locally advanced or metastatic unresectable pancreatic cancer who received the CCR2-specific antagonist CCX872 in combination with FOLFIRINOX [103]. Fifty patients with pancreatic cancer were treated and the 18-month overall survival rate was 29%. The previously reported 18-month overall survival rate for the FOLFIRINOX single-agent regimen was 18.6%, indicating the better treatment benefit in the combination therapy than single agents [104]. Various clinical trials targeting the CCL2–CCR2 axis are currently underway as shown in Table 2 and the results are awaited. Not only clinical trials to examine the effect of CCR2 inhibitor but also investigations to narrow down the patients who can be expected the effect of the CCL2–CCR2 axis targeted agents by confirming the expression of CCR2 with imaging tests are conducted.

Table 2. Ongoing clinical trials of CCR2 inhibitors and CCR2 imaging.

| Trial ID   | Intervention                                                                 | Target                                | Randomize | Patient Size |
|------------|------------------------------------------------------------------------------|---------------------------------------|-----------|--------------|
| NCT03496662| Arm A: BMS-813160+Nivolumab/Gemcitabine/Nab-paclitaxel<br>Arm B: Gemcitabine/Nab-paclitaxel<br>Arm C: BMS-813160/Nivolumab/Gemcitabine/Nab-paclitaxel (dose expansion) | Locally advanced pancreatic ductal adenocarcinoma | No        | 53           |
| NCT03767582| Phase I<br>Arm A: BMS-813160/Nivolumab/GVAX<br>Phase II<br>Arm B: BMS-813160/Nivolumab<br>Arm C: BMS-813160/Nivolumab/GVAX | Locally advanced pancreatic ductal adenocarcinoma | Yes       | 30           |
| NCT04123379| Non-small cell lung cancer<br>Arm A: Nivolumab/BMS-813160<br>Arm B: Nivolumab/BMS-96253<br>Arm C: Nivolumab<br>Arm D: Nivolumab/BMS-813160 | Non-small cell lung cancer Hepatocellular carcinoma | Yes       | 50           |
| NCT03184870| Arm A: BMS-813160/5-FU/Leucovorin/Infusor<br>Arm B: BMS-813160/Nab-paclitaxel/Gemcitabine<br>Arm C: BMS-813160/Nivolumab<br>Arm D: BMS813160/Nab-paclitaxel/Gemcitabine/Nivolumab<br>Arm E: 5-FU/Leucovorin/Infusor<br>Arm F: Nab-paclitaxel/Gemcitabine<br>Arm G: BMS-813160 | Colorectal cancer Pancreatic cancer | No        | 348          |
| NCT02996110| Arm A: Nivolumab/Ipilimumab<br>Arm B: Nivolumab/Relatlimab<br>Arm C: Nivolumab/BMS-96253<br>Arm D: Nivolumab/BMS-813160 | Advanced renal cell carcinoma | Yes       | 200          |
Table 2. Cont.

| Trial ID   | Intervention                                                                 | Target                  | Randomize | Patient Size |
|------------|------------------------------------------------------------------------------|-------------------------|-----------|--------------|
| NCT03851237| Arm 1A: Receive treatment with upfront surgery such as Whipple procedure/64Cu-DOTA-ECL1i-PET-CT imaging Arm 1B: Standard of care chemotherapy/64Cu-DOTA-ECL1i-PET-CT imaging | Pancreatic ductal adenocarcinoma | No        | 75           |
| NCT04537403| Arm 1A: Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery/64Cu-DOTA-ECL1i-PET-CT imaging Arm 1B: Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery/64Cu-DOTA-ECL1i-PET-CT imaging | Carotid atherosclerosis | No        | 100          |

1 CCR2/5-inhibitor; 2 granulocyte-macrophage colony-stimulating factor-secreting allogeneic tumor cells; 3 human monoclonal antibody that binds to and inhibits IL-8; 4 Imaging CCR2 Receptors; 5-FU, 5fluorouracil; 64Cu-DOTA-ECL1i-PET-CT imaging, Imaging CCR2 Receptors.

Losartan, a type I angiotensin II receptor antagonist, is reported to have the potential to act as direct CCR2 antagonists. Losartan and its primary metabolite, EXP-3174, inhibit CCL2-mediated monocyte recruitment to the metastatic site through the inhibition of CCL2-induced Erk1/2 activation and significantly reduce the metastatic burden in breast and colon cancer models [105]. Similarly, type I angiotensin II receptors were reported to regulate CCL2 in prostate cancer and pancreatic cancer cells, suggesting that losartan, and potentially other type I angiotensin II receptor blockers, could be repurposed for use in cancer immunotherapy [106,107].

Preclinical studies using the mouse model were also reported. Inhibition of CCL2 improved radiation resistance using mice transplanted with pancreatic duct adenocarcinoma cell lines [54]. In a preclinical study using mouse transplanted with a cabazitaxel-resistant prostate cancer cell line, inhibition of the CCL2–CCR2 axis released cabazitaxel-resistance and suppressed tumor growth in mice treated concurrently with cabazitaxel and CCR2 antagonist [30]. Administration of CCR2 inhibitor to liver metastasis model mice for colorectal cancer improved responsiveness to chemotherapy and prolonged overall survival [6]. Interestingly, in a mouse model of metastatic breast cancer, administration of anti-CCL2 antibody suppressed metastasis, while interruption of CCL2 inhibition caused metastatic overshoot and accelerated death [108]. These results may confuse the story of mechanisms in the CCL2–CCR2 axis contributing to cancer progression.

5. Discussion

Although many studies have proven the key roles of the CCL2–CCR2 axis in tumor progression in a variety of cancers, there are no clinically available drugs that can modulate the CCL2–CCR2 axis as anticancer agents so far. As described earlier, a high serum CCL2 level may reflect the activity of cancer cells because CCL2 is produced by them; however, some studies have reported conflicting results that a low serum CCL2 level contributed to a worse prognosis in cancer patients [109]. This discrepancy among clinical data suggests that there may be unidentified mechanisms of the CCL2–CCR2 axis with regard to the inhibition of cancer cell activation, and the dynamics of CCL2 in sera and the tumor microenvironment may be different among various cancers. Moreover, the application of agents for the blockade of the CCL2–CCR2 axis may be narrowed down to obtain better efficacy. As cancer cells or associated cells in the tumor microenvironment must express CCR2, and the CCL2–CCR2 axis may be more important in cancers with high immunogenicity than those with low immunogenicity and that can hardly mobilize immune cells into the tumor microenvironment. CCL2 activates TAMs and MDSCs that can activate regulatory T lymphocytes. Regulatory T lymphocytes can inhibit the activity of cytotoxic T lymphocytes that play a key role in the immune system to eliminate cancer cells in the tumor microenvironment [55]. According to this sequential mechanism, programmed death-ligand 1 or programmed cell death protein 1 inhibitors that impede immune tolerance between cytotoxic T lymphocytes and cancer cells may synergistically...
function with the blockade of the CCL2–CCR2 axis as a combination anticancer treatment. Interestingly, the therapeutic effects of combination treatment combining CCL2 antagonist and anti-programmed death-ligand 1 antibody in lung tumor-bearing mice decreased MDSC in the periphery and tumor through an enhanced CD4+ and CD8+ T lymphocyte infiltration and increased the survival time compared to single agent alone [110].

The performance of the drug itself in exerting its potential effect to suppress cancer cell activity is also important to consider. Measurement of free CCL2 concentration following carlumab administration revealed a rapid fall in free CCL2 as expected; however, post-treatment free CCL2 concentrations rapidly rebounded and quickly exceeded pretreatment serum concentrations. These unexpected results suggest that carlumab was ineffective at suppressing free CCL2 concentration for a clinically meaningful period of time. As no apparent increase in CCL2 production rate was observed when the dose was increased from 1 to 50 mg/kg in cynomolgus monkeys, dose-escalation might be needed to adequately and constitutively suppress free CCL2 concentration [101]. PF-04136309 showed that the level of CCR2-positive inflammatory monocytes decreased in the peripheral blood but did not accumulate in the bone marrow [99]. The chemical modification of these agents may improve the anticancer effects.

The CCL2–CCR2 axis functions physiologically in various organs such as the lungs and digestive tract where a variety of immune cells accumulate. Blockade of the CCL2–CCR2 axis potentially causes unexpected effects in such organs. Although it is unclear whether each adverse event attributes to the blockade of the CCL2–CCR2 axis because PF-04136309 was used in combination with cytotoxic agents in a single-arm study, pulmonary toxicity and diarrhea as well as myelosuppression were reported as severe adverse events in clinical trials [99]. Although the incidence of treatment-related severe adverse events was not so high, grade 4 gastrointestinal perforation and grade 5 multi-organ failure were also reported in carlumab study for prostate cancer patients even any other anti-cancer agents were concurrently started [98,99,101]. In case an agent designed for the blockade of the CCL2–CCR2 axis is used in combination therapy, strict attention should be paid to the choice of agents being used together not to amplify treatment-related adverse events. However, the adverse events of blocking the CCL2-CCR2 axis are still not fully investigated, and further data should be accumulated in future clinical trials. As previously mentioned, losartan, and potentially other type I angiotensin II receptor blockers, might be repurposed for use in cancer immunotherapy to prevent severe adverse events; however, the clinically effective dose as anticancer agents should be investigated [106,107]. A recent study reported that the coffee compound kahweol acetate and cafestol can reduce not only CCL2 secretion but also CCR2 expression on prostate cancer cells [111]. These food-derived agents may be potential candidates for therapy in the future, especially as part of a combination therapy approach for the treatment of cancers with high immunogenicity.

In summary, to achieve sufficient efficacy of CCL2–CCR2-targeted therapy for cancer patients, it is not sufficient to target cancer cells or immune cells alone and it is necessary to fully elucidate the physiological functions of the CCL2–CCR2 axis against a variety of normal cells expressing CCR2.

Author Contributions: Conceptualization, K.I.; writing—original draft preparation, K.I. and H.I.; writing—review and editing, K.I.; supervision, A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| Akt          | Protein kinase B |
| CAF          | Cancer-associated Fibroblast |
| CCL2         | C-C motif ligand 2 |
| CCR2         | C-C Chemokine Receptor 2 |
| EMT          | Epithelial-Mesenchymal Transition |
FAP Fibroblast Activation Protein
FOLFIRINOX leucovorin, fluorouracil, irinotecan, and oxaliplatin
HCC Hepatocellular Carcinoma
IL Interleukin
JAK2 Janus kinase2
MAPK Mitogen-activated Protein Kinase
MDSC Myeloid-Derived Immune Suppressor Cell
MMP Matrix Metalloproteinase
NHL Non-Hodgkin’s Lymphoma
PIPKIγ Phosphatidylinositol phosphate kinase gamma
PI3K Phosphatidylinositol 3-kinase
PSA Prostate-specific antigen
STAT3 Signal Transducers and Activator of Transcription 3
TAM Tumor-Associated Macrophage

References

1. Matsushima, K.; Larsen, C.G.; DuBois, G.C.; Oppenheim, J.J. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. *J. Exp. Med.* 1989, 169, 1485–1490. [CrossRef]
2. Van, C.E.; Van, D.J.; Opdenakker, G. The MCP/eotaxin subfamily of CC chemokines. *Cytokine. Growth Factor Rev.* 1999, 10, 61–86.
3. Depshane, S.L.; Kreml, S.; Amin, S.; Sawaya, B.E. Monocyte chemoattractant protein-1 (MCP-1): An overview. *J. Interferon Cytokine Res.* 2009, 29, 313–326. [CrossRef] [PubMed]
4. Rossarohoff, R.M. The chemokine system in neuroinflammation: An update. *J. Infect. Dis.* 2002, 186, S152–S156. [CrossRef] [PubMed]
5. Hughes, C.E.; Nibbs, R.J.B. A guide to chemokines and their receptors. *FEBS J.* 2018, 285, 2944–2971. [CrossRef]
6. Charo, I.F.; Myers, S.J.; Herman, A.; Franci, A.; Connolly, A.J.; Coughlin, S.R. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. *Proc. Natl. Acad. Sci. USA* 1994, 91, 2752–2756. [CrossRef] [PubMed]
7. Panee, J. Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes. *Cytokine* 2012, 60, 1–12. [CrossRef]
8. Engin, A.B. Adipocyte-Macrophage Cross-Talk in Obesity. *Adv. Exp. Med. Biol.* 2017, 960, 327–343.
9. Kadomoto, S.; Izumi, K.; Mizokami, A. The CCL20-CCR6 Axis in Cancer Progression. *Int. J. Mol. Sci.* 2020, 21, 5186. [CrossRef]
10. Korbecki, J.; Olbromski, M.; Dziegiel, P. CCL18 in the Progression of Cancer. *Int. J. Mol. Sci.* 2020, 21, 7955. [CrossRef]
11. Czemplik, M.; Kulma, A.; Wang, Y.F.; Szopa, J. Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1. *Curr. Med. Chem.* 2017, 24, 1453–1468. [CrossRef] [PubMed]
12. Loberg, R.D.; Ying, C.; Craig, M.; Yan, L.; Snyder, L.A. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. *Neoplasia* 2007, 9, 556–562. [CrossRef] [PubMed]
13. Loberg, R.D.; Day, L.L.; Harwood, J.; Ying, C.; John, L.N.S.; Giles, R.; Neeley, C.K.; Pienta, K.j. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. *Neoplasia* 2006, 8, 578–586. [CrossRef] [PubMed]
14. Chiu, H.Y.; Sun, K.H.; Chen, S.Y.; Wang, H.H.; Lee, M.Y.; Tsou, Y.C.; Jwo, S.C.; Sun, G.H.; Tang, S.J. Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells. *Cytokine* 2012, 59, 423–432. [CrossRef]
15. Gao, L.; Wang, F.Q.; Li, H.M.; Yang, J.G.; Ren, J.G.; He, K.F.; Liu, B.; Zhang, W.; Zhao, Y.F. CCL2/EGF positive feedback loop between cancer cells and macrophages promotes cell migration and invasion in head and neck squamous cell carcinoma. *Oncotarget* 2016, 7, 87037–87051. [CrossRef]
16. Park, J.; Ryu, D.R.; Li, J.J.; Jung, D.S.; Kwak, S.J.; Lee, S.H.; Yoo, T.H.; Han, S.H.; Lee, J.E.; Kim, D.K.; et al. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. *Am. J. Physiol. Renal Physiol.* **2008**, *295*, 749–757. [CrossRef]

17. Dagouassat, M.; Sufee, N.; Hlawaty, H.; Haddad, O.; Charni, F.; Laguillier, C.; Vassy, R.; Martin, L.; Schischmanoff, P.O.; Gattegno, L.; et al. Monocyte chemoattractant protein-1 (MCP-1)/CCR2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. *Int. J. Cancer* **2010**, *126*, 1095–1108. [CrossRef]

18. Tang, C.H.; Tsai, C.C. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. *Biochem. Pharmacol.* **2012**, *83*, 335–344. [CrossRef]

19. Kudo-Saito, C.; Shirako, H.; Ohike, M.; Tsukamoto, N.; Kawakami, Y. CCL2 is critical for immunosuppression to promote cancer metastasis. *Clin. Exp. Metastasis* **2013**, *30*, 393–405. [CrossRef]

20. Chen, W.; Gao, Q.; Han, S.; Pan, F.; Fan, W. The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling. *Tumour Biol.* **2015**, *36*, 973–981. [CrossRef]

21. Tsai, Y.C.; Chen, W.Y.; Abou-Kheir, W.; Zeng, T.; Yin, J.J.; Bahmad, H.; Lee, Y.C.; Liu, Y.N. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2. *Biochim. Biophys. Acta Mol. Basis Dis.* **2018**, *1864*, 1717–1727. [CrossRef] [PubMed]

22. Ling, Z.; Yang, X.; Chen, X.; Xia, J.; Cheng, B.; Tao, X. CCL2 promotes cell migration by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. *J. Oral Pathol. Med.* **2019**, *48*, 477–482. [CrossRef] [PubMed]

23. Roblek, M.; Protsyuk, D.; Becker, P.F.; Stefanescu, C.; Gorzelanny, C.; Garzon, J.F.G.; Knopfova, L.; Heikenwalder, M.; Luckow, B.; Schneider, S.W.; et al. CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis. *Mol. Cancer Res.* **2019**, *17*, 783–793. [CrossRef] [PubMed]

24. Lee, S.H.; Kang, H.Y.; Kim, K.S.; Nam, B.Y.; Paeng, J.; Kim, S.; Li, J.J.; Park, J.T.; Kim, D.K.; Han, S.H.; et al. The monocyte chemoattractant protein-1 (MCP-1)/CCR2 system is involved in peritoneal dialysis-related epithelial-mesenchymal transition of peritoneal mesothelial cells. *Lab. Investig.* **2012**, *92*, 1698–1711. [CrossRef] [PubMed]

25. Cioni, B.; Nevedomskaya, E.; Melis, M.H.M.; van Burgsteden, J.; Stelloo, S.; Hodel, E.; Spinozzi, D.; de Jong, J.; van der Poel, H.; de Boer, J.P.; et al. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration. *Mol. Oncol.* **2018**, *12*, 13081323. [CrossRef] [PubMed]

26. Yue, Y.; Lian, J.; Wang, T.; Luo, C.; Yuan, Y.; Qin, G.; Zhang, B.; Zhang, Y. Interleukin-33-nuclear factor-κB signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells. *Cancer Sci.* **2020**, *111*, 795–806. [CrossRef] [PubMed]

27. Rao, Q.; Chen, Y.; Yeh, C.R.; Ding, J.; Li, L.; Chang, C.; Yeh, S. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. *OncoTargets and Therapy* **2016**, *7*, 7842–7855. [CrossRef]

28. Izumi, K.; Fang, L.Y.; Mizokami, A.; Namiki, M.; Li, L.; Lin, W.J.; Chang, C. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. *EMBO Mol. Med.* **2013**, *5*, 1383–1401. [CrossRef]

29. Moalake, A.; Izumi, K.; Shigehara, K.; Natsagdorj, A.; Iwamoto, H.; Kadomoto, S.; Takezawa, Y.; Machioka, K.; Narimoto, K.; Namiki, M.; et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL2/CCR2 axis. *Oncotarget* **2017**, *8*, 9739–9751. [CrossRef]

30. Natsagdorj, A.; Izumi, K.; Hiratsuka, K.; Machioka, K.; Iwamoto, H.; Naito, R.; Makino, T.; Kadomoto, S.; Shigehara, K.; Kadono, Y.; et al. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. *Cancer Sci.* **2019**, *110*, 279–288. [CrossRef]

31. Qian, D.Z.; Rademacher, B.L.; Pittsengerbar, J.; Huang, C.Y.; Myrthe, A.; Higano, C.S.; Garzotto, M.; Nelson, P.S.; Beer, T.M. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. *Prostate* **2010**, *70*, 433–442. [CrossRef] [PubMed]

32. Li, D.; Ji, H.; Niu, X.; Yin, L.; Wang, Y.; Gu, Y.; Wang, J.; Zhou, X.; Zhang, H.; Zhang, Q. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. *Cancer Sci.* **2020**, *111*, 47–58. [CrossRef] [PubMed]
Zhang, Q.W.; Liu, L.; Gong, C.Y.; Shi, H.S.; Zeng, Y.H.; Wang, X.Z.; Zhao, Y.W.; Wei, Y.Q. Prognostic...

Xue, J.; Ge, X.; Zhao, W.; Xue, L.; Dai, C.; Lin, F.; Peng, W. PIPK1gamma Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling. *J. Immunol. Res.* 2019, 2019, 3690561. [CrossRef] [PubMed]

Grossman, J.G.; Nywening, T.M.; Belt, B.A.; Panni, R.Z.; Krasnick, B.A.; DeNardo, D.G.; Hawkins, W.G.; Goedegebuure, S.P.; Linehan, D.C.; Fields, R.C. Recruitment of CCR2(+) tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. *Oncoviroimmunology* 2018, 7, e1470729. [CrossRef] [PubMed]

An, J.; Xue, Y.; Long, M.; Zhang, G.; Zhang, J.; Su, H. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. *Oncotarget* 2017, 8, 39230–39240. [CrossRef] [PubMed]

Furukawa, S.; Soeda, S.; Kiko, Y.; Suzuki, O.; Hashimoto, Y.; Watanabe, T.; Nishiyama, H.; Tasaki, K.; Hojo, H.; Abe, M.; et al. MCP-1 promotes invasion and adhesion of human ovarian cancer cells. *Anticancer Res.* 2013, 33, 4785–4790.

Moisan, F.; Francisco, E.B.; Brozovic, A.; Duran, G.E.; Wang, Y.C.; Chaturvedi, S.; Seetharam, S.; Snyder, L.A.; Doshi, P.; Sikic, B.I. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. *Mol. Oncol.* 2014, 8, 1231–1239. [CrossRef]

Wang, T.; Zhan, Q.; Peng, X.; Qiu, Z.; Zhao, T. CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. *Oncol. Lett.* 2018, 16, 1267–1274. [CrossRef]

Xu, W.; Wei, Q.; Han, M.; Zhou, B.; Wang, H.; Zhang, J.; Wang, Q.; Sun, J.; Feng, L.; Wang, S.; et al. CCL2SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer. *Int. J. Biol. Sci.* 2018, 14, 1054–1066. [CrossRef]

Lu, H.; Clauser, K.R.; Tam, W.L.; Fröse, J.; Ye, X.; Eaton, E.N.; Reinhardt, F.; Donnenberg, V.S.; Bhargava, R.; Carr, S.A.; et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. *Nat. Cell. Biol.* 2014, 16, 1105–1117. [CrossRef]

Ostuni, R.; Kratochvill, F.; Murray, P.J.; Natoli, G. Macrophages and cancer: From mechanisms to therapeutic implications. *Trends. Immunol.* 2015, 36, 229–239. [CrossRef] [PubMed]

Cortés, M.; Sanchez-Moral, L.; de Barrios, O.; Fernández-Aceñero, M.J.; Martinez-Campanario, M.C.; Esteve-Codina, A.; Darling, D.S.; Györffy, B.; Lawrence, T.; Dean, D.C.; et al. Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. *EMBO J.* 2017, 36, 3336–3355. [CrossRef] [PubMed]

Lin, T.H.; Izumi, K.; Lee, S.O.; Lin, W.J.; Yeh, S.; Chang, C. Anti-androgen receptor ASC-J9 versus antiandrogens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. *Cell. Death. Dis.* 2013, 4, e764. [CrossRef] [PubMed]

Qian, B.Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. *Cell* 2010, 141, 39–51. [CrossRef]

Zheng, X.; Weigert, A.; Reu, S.; Guenther, S.; Mansouri, S.; Bassaly, B.; Gattenlöhrner, S.; Grimminger, F.; Pullamsetti, S.; Seeger, W.; et al. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. *Cancer Res.* 2020, 80, 4414–4425. [CrossRef]

Zheng, Z.W.; Liu, L.; Gong, C.Y.; Shi, H.S.; Zeng, Y.H.; Wang, X.Z.; Zhao, Y.W.; Wei, Y.Q. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. *PLoS ONE* 2012, 7, e50946. [CrossRef]

Pullamsetti, S.; Seeger, W.; et al. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. *Cancer Res.* 2020, 80, 4414–4425. [CrossRef]

Lissbrant, I.F.; Stattin, P.; Wikstrom, P.; Damber, J.E.; Egevad, L.; Bergh, A. Tumor associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival. *Int. J. Oncol.* 2000, 17, 445451. [CrossRef]

Zhao, J.; Liu, H.; Zhang, X.; Zhang, W.; Liu, L.; Yu, Y.; Ren, S.; Yang, Q.; Liu, B.; Li, J.; et al. Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer. *Cancer. Biother. Radiopharm.* 2020. [CrossRef]

Mavili, H.S.; Isisag, A.; Tan, A.; Miskioglu, M.; Baraz, L.S.; Nese, N. Relationship of Tumor-Associated Macrophage Population Detected by CD68 PG-M1, CD68 KP1, and CD163 with Latent EBV Infection and Prognosis in Classical Hodgkin Lymphoma. *Turk. Patoloji. Derg.* 2020. [CrossRef]
66. Wang, W.W.; Ang, S.F.; Kumar, R.; Heah, C.; Utama, A.; Tania, N.P.; Li, H.; Tan, S.H.; Poo, D.; Choo, S.P.; et al.

68. Lebrecht, A.; Grimm, C.; Lantzsch, T.; Ludwig, E.; Hefler, L.; Ulbrich, E.; Koelbl, H. Monocyte chemoattractant

63. Szczepanik, A.M.; Siedlar, M.; Szura, M.; Kibil, W.; Brzuszkiewicz, K.; Brandt, P.; Kulig, J. Preoperative serum

59. Öhlund, D.; Elyada, E.; Tuveson, D. Fibroblast heterogeneity in the cancer wound.

57. Yang, X.; Lin, Y.; Shi, Y.; Li, B.; Liu, W.; Yin, W.; Dang, Y.; Chu, Y.; Fan, J.; He, R. FAP Promotes

56. Chun, E.; Lavoie, S.; Michaud, M.; Gallini, C.A.; Kim, J.; Soucy, G.; Odze, R.; Glickman, J.N.; Garrett, W.S.

55. Vetsika, E.K.; Koukos, A.; Kotsakis, A. Myeloid-Derived Suppressor Cells: Major Figures that Shape the

54. Kalbasi, A.; Komar, C.; Tooker, G.M.; Liu, M.; Lee, J.W.; Gladney, W.L.; Ben-Josef, E.; Beatty, G.L. TumorDerived

CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2017, 23, 137–148. [CrossRef] [PubMed]

53. Kitamura, T.; Qian, B.Z.; Soong, D.; Cassetta, L.; Noy, R.; Sugano, G.; Kato, Y.; Li, J.; Pollard, J.W. CCL2induced

52. Chang, S.J.; Tu, H.P.; Lai, Y.C.; Luo, C.W.; Nejo, T.; Tanaka, S.; Chai, C.Y.; Kwan, A.L. Increased Vascular

51. Chen, Y.L. Prognostic significance of tumor-associated macrophages in patients with nasopharyngeal

carcinoma: A meta-analysis. Medicine 2020, 99, e21999. [CrossRef] [PubMed]

50. Öhlund, D.; Elyada, E.; Tuveson, D. Fibroblast heterogeneity in the cancer wound.

49. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer.

48.徽. Heiskala, M.; Leidenius, M.; Joensuu, K.; Heikkilä, P. High expression of CCL2 in tumor cells and abundant

47. Pausch, T.M.; Aue, E.; Wirsik, N.M.; Freire, V.A.; Shen, Y.; Radhakrishnan, P.; Hackert, T.; Schneider, M.; Schmidt, T. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the

CCL8 and the CCL2 axes. Sci. Rep. 2020, 10, 5420. [CrossRef]

46. Vetsika, E.K.; Koukos, A.; Kotsakis, A. Myeloid-Derived Suppressor Cells: Major Figures that Shape the

45. Chun, E.; Lavoie, S.; Michaud, M.; Gallini, C.A.; Kim, J.; Soucy, G.; Odze, R.; Glickman, J.N.; Garrett, W.S.

44. Yoshidome, H.; Kohno, H.; Shida, T.; Kimura, F.; Shimizu, H.; Ohtsuka, M.; Nakatani, Y.; Miyazaki, M.

43. Kadono, Y.; Miyamoto, H.; et al. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget 2016, 7, 8389–8398. [CrossRef] [PubMed]

42. Schmitz, M.; et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the

JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 2012, 22, 91–105. [CrossRef] [PubMed]

41. Izumi, K.; Mizokami, A.; Lin, H.P.; Ho, H.M.; Iwamoto, H.; Maolake, A.; Natsagdorj, A.; Kitagawa, Y.; Kadoy, Y.; Miyamoto, H.; et al. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget 2016, 7, 8389–8398. [CrossRef] [PubMed]

40. Pausch, T.M.; Aue, E.; Wirsik, N.M.; Freire, V.A.; Shen, Y.; Radhakrishnan, P.; Hackert, T.; Schneider, M.; Schmidt, T. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the

CCL8 and the CCL2 axes. Sci. Rep. 2020, 10, 5420. [CrossRef]

39. Öhlund, D.; Elyada, E.; Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 2014, 211, 1503–1523. [CrossRef]

38. Chang, S.J.; Tu, H.P.; Lai, Y.C.; Luo, C.W.; Nejo, T.; Tanaka, S.; Chai, C.Y.; Kwan, A.L. Increased Vascular

37. Pausch, T.M.; Aue, E.; Wirsik, N.M.; Freire, V.A.; Shen, Y.; Radhakrishnan, P.; Hackert, T.; Schneider, M.; Schmidt, T. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the

CCL8 and the CCL2 axes. Sci. Rep. 2020, 10, 5420. [CrossRef]

36. Szczepanik, A.M.; Siedlar, M.; Szura, M.; Kibl, W.; Brzuszkiewicz, K.; Brandt, P.; Kulig, J. Preoperative serum

chemokine (C-C motif) ligand 2 levels and prognosis in colorectal cancer. Pol. Arch. Med. Wewn. 2015, 125, 443–451. [CrossRef] [PubMed]

35. Yoshidome, H.; Kohno, H.; Shida, T.; Kimura, F.; Shimizu, H.; Ohotsuka, M.; Nakatani, Y.; Miyazaki, M. Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. Int. J. Oncol. 2009, 34, 923–930. [CrossRef]

34. Hu, H.; Sun, L.; Guo, C.; Liu, Q.; Zhou, Z.; Peng, L.; Pan, J.; Yu, L.; Lou, J.; Yang, Z.; et al. Tumor cellmicroenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin. Cancer Res. 2009, 15, 5485–5493. [CrossRef]

33. Wang, W.W.; Ang, S.F.; Kumar, R.; Heah, C.; Utama, A.; Tania, N.P.; Li, H.; Tan, S.H.; Poo, D.; Choo, S.P.; et al. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS ONE 2013, 8, e68904. [CrossRef]

32. Chew, V.; Chen, J.; Lee, D.; Loh, E.; Lee, J.; Lim, K.H.; Weber, A.; Slankamenac, K.; Poon, R.T.; Yang, H.; et al. Chemokine-driven lymphocyte infiltration: An early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012, 61, 427–438. [CrossRef]

31. Lebrecht, A.; Grimm, C.; Lantzsch, T.; Ludwig, E.; Hefler, L.; Ulbrich, E.; Koelbl, H. Monocyte chemoattractant

protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004, 25, 14–17. [CrossRef]

30. Heiskala, M.; Leidenius, M.; Joensuu, K.; Heikkilä, P. High expression of CCL2 in tumor cells and abundant

infiltration with CD14 positive macrophages predict early relapse in breast cancer. Virchows. Arch. 2019, 474, 3–12. [CrossRef]

29. Yao, M.; Yu, E.; Staggs, V.; Fan, F.; Cheng, N. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. Mod. Pathol. 2016, 29, 810–823. [CrossRef]
71. Ueno, T.; Toi, M.; Saji, H.; Muta, M.; Bando, H.; Kuroi, K.; Koike, M.; Inadera, H.; Matsushima, K. Significance of macrophage chemotactic protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000, 6, 3282–3289. [PubMed]

72. Valković, T.; Lucin, K.; Krstulja, M.; Dobi-Babić, R.; Jonjić, N. Expression of monocyte chemotactic protein1 in human invasive ductal breast cancer. Pathol. Res. Pract. 1998, 194, 335–340. [CrossRef]

73. Monti, P.; Leone, B.E.; Marchesi, F.; Balzano, G.; Zerbi, A.; Scaltrini, F.; Pasquali, C.; Calori, G.; Pessi, F.; Sperti, C.; et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: Regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 2003, 63, 7451–7461. [PubMed]

74. Feng, L.; Qi, Q.; Wang, P.; Chen, H.; Chen, Z.; Meng, Z.; Liu, L. Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Acta Gastroenterol. Belg. 2020, 83, 295–299.

75. Sanford, D.E.; Belt, B.A.; Panni, R.Z.; Mayer, A.; Deshpande, A.D.; Carpenter, D.; Mitchem, J.B.; PlambeckSuess, S.M.; Worley, L.A.; Goetz, B.D.; et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 2013, 19, 3404–3415. [CrossRef]

76. Lewis, H.L.; Chakedis, J.M.; Talbert, E.; Haverick, E.; Rajasekera, P.; Hart, P.; Bloomston, M.; Dillhoff, M.; Pawlik, T.M.; Guttridge, D.; et al. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. J. Surg. Oncol. 2018, 117, 1260–1266. [CrossRef]

77. Talbert, E.E.; Lewis, H.L.; Farren, M.R.; Ramsey, M.L.; Chakedis, J.M.; Rajasekera, P.; Haverick, E.; Sarna, A.; Bloomston, M.; Pawlik, T.M.; et al. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J. Cachexia Sarcopenia Muscle 2018, 9, 358–368. [CrossRef]

78. Anber, N.H.; El-Sebaie, A.H.; Darwish, N.H.E.; Mousa, S.A.; Shamaa, S.S. Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma. Ann. Hematol. 2019, 98, 413–422. [CrossRef]

79. Li, Y.L.; Shi, Z.H.; Wang, X.; Gu, K.S.; Zhai, Z.M. Prognostic value of some inflammatory markers in patients with lymphoma. Biosei. Rep. 2019, 39. [CrossRef]

80. Valković, T.; Duletić-Načinović, A.; Stifer, S.; Hasan, M.; Hadžisejdić, I.; Zombori, D.; Grabovac, B.; Jonjić, N. Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma. Clin. Exp. Med. 2010, 10, 229–235. [CrossRef]

81. Wu, J.; Liu, X.; Wang, Y. Predictive value of preoperative serum CCL2, CCL18, and VEGF for the patients with gastric cancer. BMC Clin. Pathol. 2013, 13, 15. [CrossRef] [PubMed]

82. Tas, F.; Karabulut, S.; Serilmaz, M.; Karabulut, M.; Duranyildiz, D. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. Cancer Chemother. Pharmacol. 2016, 77, 127–131. [CrossRef] [PubMed]

83. Baj-Krzyworzeka, M.; Węglarczyk, K.; Baran, J.; Szczepanik, A.; Szura, M.; Siedlar, M. Elevated level of some chemokines in plasma of gastric cancer patients. Cent. Eur. J. Immunol. 2016, 41, 358–362. [CrossRef] [PubMed]

84. Tao, L.L.; Shi, S.J.; Chen, L.B.; Huang, G.C. Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia. World J. Gastroenterol. 2014, 20, 4421–4427. [CrossRef]

85. Zhang, J.; Yan, Y.; Cui, X.; Zhang, J.; Yang, Y.; Li, H.; Wu, H.; Li, J.; Wang, L.; Li, M.; et al. CCL2 expression correlates with Snail expression and affects the prognosis of patients with gastric cancer. Pathol. Res. Pract. 2017, 213, 217–221. [CrossRef]

86. Liu, H.; Shen, Z.; Wang, X.; Zhang, H.; Qin, J.; Qin, X.; Xu, J.; Sun, Y. Increased expression of C-C motif ligand 2 associates with poor prognosis in patients with gastric cancer after gastrectomy. Tumour Biol. 2016, 37, 3285–3293. [CrossRef]

87. Heffler, L.; Tempfer, C.; Heinze, G.; Mayerhofer, K.; Breitenecker, G.; Leodolter, S.; Reinthaller, A.; Kainz, C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br. J. Cancer 1999, 81, 855859. [CrossRef]

88. Fader, A.N.; Rasool, N.; Vaziri, S.A.; Kozuki, T.; Faber, P.W.; Elson, P.; Biscotti, C.V.; Michener, C.M.; Rose, P.G.; Rojas-Espaillat, L.; et al. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010, 30, 4791–4798.
98. Amann, B.; Perabo, F.G.; Wirger, A.; Hugenschildt, H.; Schultz-Seeemann, W. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. *Br. J. Urol.* 1998, 82, 118–121. [CrossRef] [PubMed]

99. Arakaki, R.; Yamasaki, T.; Kawano, T.; Shibasaki, N.; Sakamoto, H.; Utsunomiya, N.; Sumiyoshi, T.; Shibuya, S.; Tsuruyama, T.; Nakamura, E.; et al. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. *Cancer Med.* 2016, 5, 2920–2933. [CrossRef] [PubMed]

100. Wang, Z.; Xie, H.; Zhou, L.; Liu, Z.; Fu, H.; Zhu, Y.; Xu, L.; Xu, J. CCL2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. *Oncotarget* 2016, 7, 51525–51534. [CrossRef] [PubMed]

101. Lu, X.; Qian, C.N.; Mu, Y.G.; Li, N.W.; Li, S.; Zhang, H.B.; Li, S.W.; Wang, F.L.; Guo, X.; Xiang, Y.Q. Serum CCL2 and serum TNF-α-two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. *Eur. J. Cancer* 2011, 47, 339–346. [CrossRef] [PubMed]

102. Tanaka, K.; Kurebayashi, J.; Sohda, M.; Nomura, T.; Prabhakar, U.; Yan, L.; Sonoo, H. The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence. *Thyroid* 2009, 19, 21–25. [CrossRef]

103. Kuratsu, J.; Yoshizato, K.; Yoshimura, T.; Leonard, E.J.; Takeshima, H.; Ushio, Y. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. *J. Natl. Cancer Inst.* 1993, 85, 1836–1839. [CrossRef]

104. Nywening, T.M.; Wang-Gillam, A.; Sanford, D.E.; Belt, B.A.; Parini, R.Z.; Cusworth, B.M.; Toriola, A.T.; Nieman, R.K.; Worley, L.A.; Yano, M.; et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1b trial. *Lancet Oncol.* 2016, 17, 651–662. [CrossRef]

105. Noel, M.; O’Reilly, E.M.; Wolpin, B.M.; Ryan, D.P.; Bullock, A.J.; Britten, C.D.; Linehan, D.C.; Belt, B.A.; Gamelin, E.C.; Ganguly, B.; et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. *Investig. New Drugs* 2020, 38, 800–811. [CrossRef]

106. Sandhu, S.K.; Papadopoulos, K.; Fong, P.C.; Patnaik, A.; Messiou, C.; Olmos, D.; Wang, G.; Tromp, B.J.; Puchalski, T.A.; Balkwill, F.; et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. *Cancer Chemother. Pharmacol.* 2013, 71, 1041–1050. [CrossRef]

107. Pienta, K.J.; Machtels, J.P.; Schrijvers, D.; Alekseev, B.; Shkolnik, M.; Crabb, S.J.; Li, S.; Seetharam, S.; Puchalski, T.A.; Takimoto, C.; et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. *Investig. New Drugs* 2013, 31, 760–768. [CrossRef] [PubMed]

108. Vela, M.; Aris, M.; Llorente, M.; Garcia-Sanz, J.A.; Kremer, L. Chemokine receptor-specific antibodies in cancer immunotherapy: Achievements and challenges. *Front. Immunol.* 2015, 6, 12. [CrossRef] [PubMed]

109. Linehan, D.; Noel, M.S.; Hezel, A.F.; Wang-Gillam, A.; Eskens, F.; Sleijfer, S.; Desar, I.M.E.; Erdkamp, F.; Wilmink, J.; Diehl, J.; et al. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. *J. Clin. Oncol.* 2018, 36, 92. [CrossRef]

110. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardière, C.; et al. FOLFRINOX versus gemcitabine for metastatic pancreatic cancer. *N. Engl. J. Med.* 2011, 364, 1817–1825. [CrossRef]
105. Regan, D.P.; Coy, J.W.; Chahal, K.K.; Chow, L.; Kurihara, J.N.; Guth, A.M.; Kufareva, I.; Dow, S.W. The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1RIndependent Inhibition of CCR2 Signaling and Monocyte Recruitment. *J. Immunol.* 2019, 202, 3087–3102. [CrossRef]

106. Shirotake, S.; Miyajima, A.; Kosaka, T.; Tanaka, N.; Kikuchi, E.; Mikami, S.; Okada, Y.; Oya, M. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. *Am. J. Pathol.* 2012, 180, 1008–1016. [CrossRef]

107. Chehl, N.; Gong, Q.; Chipitsyna, G.; Aziz, T.; Yeo, C.J.; Arafat, H.A. Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. *J. Gastrointest. Surg.* 2009, 13, 2189–2200. [CrossRef]

108. Bonapace, L.; Coissieux, M.M.; Wyckoff, J.; Mertz, K.D.; Varga, Z.; Junt, T.; Bentires-Alj, M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. *Nature* 2014, 515, 130–133. [CrossRef]

109. Sanchez-Zauco, N.; Torres, J.; Gomez, A.; Camorlinga-Ponce, M.; Munoz-Perez, L.; Herrera-Goepfert, R.; Medrano-Guzman, R.; Giono-Cerezo, S.; Maldonado-Bernal, C. Circulating blood levels of IL-6, IFNgamma, and IL-10 as potential diagnostic biomarkers in gastric cancer: A controlled study. *BMC Cancer* 2017, 17, 384.

110. Wang, Y.; Zhang, X.; Yang, L.; Xue, J.; Hu, G. Blockade of CCL2 enhances immunotherapeutic effect of antiPD1 in lung cancer. *J. Bone Oncol.* 2018, 11, 27–32. [CrossRef]

111. Iwamoto, H.; Izumi, K.; Natsagdorj, A.; Naito, R.; Makino, T.; Kadomoto, S.; Hiratsuka, K.; Shigehara, K.; Kadono, Y.; Narimoto, K.; et al. Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. *Prostate* 2019, 79, 468–479. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.